Project ID: D2007-12U.S. Patent #8,211,858; Canada, European patents pendingU.S. Patent #7,592,422; Canada, France, Germany, Netherlands, UK patents pendingNovelty: Modified plasminogen activator inhibitor type I (PAI- 1) with significantly increased in vivo half-life and decreased activity to uroki.....
[更多]
Cardiomyopathy TreatmentA new class of oligonucleotides can be used to treat cardiomyopathy. The short, protein-interacting DNAs and RNAs (SPIDRs) are designed to selectively bind to phospholamban (PLN), a compound that inhibits SERCA, which is a necessary function for cardiac health.Results show th.....
[更多]
Though use of renewable energy has become increasingly widespread in recent years, many of these technologies remain dependent on inconstant environmental conditions, resulting in inconsistent energy production. This technology is a water-sensitive bio-hybrid material that expands and contracts in r.....
[更多]
A novel immunotherapeutic approach against drug-resistant pathogens, such as Neisseria gonorrhoeae, comprising administration to a subject a fusion protein linking Factor H to IgG Fc.
[更多]
| |< <- | [3560] [3561] [3562] [3563] [3564] [3565] [3566] [3567] [3568] [3569] [3570] | -> >| |
